title: Effects of Tamoxifen and oestrogen on histology and radiographic density in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers.
abstract: Mammographic density (MD) is a strong risk factor for breast cancer. It is altered by exogenous endocrine treatments, including hormone replacement therapy and Tamoxifen. Such agents also modify breast cancer (BC) risk. However, the biomolecular basis of how systemic endocrine therapy modifies MD and MD-associated BC risk is poorly understood. This study aims to determine whether our xenograft biochamber model can be used to study the effectiveness of therapies aimed at modulating MD, by examine the effects of Tamoxifen and oestrogen on histologic and radiographic changes in high and low MD tissues maintained within the biochamber model. High and low MD human tissues were precisely sampled under radiographic guidance from prophylactic mastectomy fresh specimens of high-risk women, then inserted into separate vascularized murine biochambers. The murine hosts were concurrently implanted with Tamoxifen, oestrogen or placebo pellets, and the high and low MD biochamber tissues maintained in the murine host environment for 3 months, before the high and low MD biochamber tissues were harvested for histologic and radiographic analyses. The radiographic density of high MD tissue maintained in murine biochambers was decreased in Tamoxifen-treated mice compared to oestrogen-treated mice (p = 0.02). Tamoxifen treatment of high MD tissue in SCID mice led to a decrease in stromal (p = 0.009), and an increase in adipose (p = 0.023) percent areas, compared to placebo-treated mice. No histologic or radiographic differences were observed in low MD biochamber tissue with any treatment. High MD biochamber tissues maintained in mice implanted with Tamoxifen, oestrogen or placebo pellets had dynamic and measurable histologic compositional and radiographic changes. This further validates the dynamic nature of the MD xenograft model, and suggests the biochamber model may be useful for assessing the underlying molecular pathways of Tamoxifen-reduced MD, and in testing of other pharmacologic interventions in a preclinical model of high MD.
authors.affiliation: Department of Surgery, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia, gracelchew@gmail.com.
authors.forename: G L
authors.initials: GL
authors.lastname: Chew
authors.forename: C W
authors.initials: CW
authors.lastname: Huo
authors.forename: D
authors.initials: D
authors.lastname: Huang
authors.forename: T
authors.initials: T
authors.lastname: Blick
authors.forename: P
authors.initials: P
authors.lastname: Hill
authors.forename: J
authors.initials: J
authors.lastname: Cawson
authors.forename: H
authors.initials: H
authors.lastname: Frazer
authors.forename: M C
authors.initials: MC
authors.lastname: Southey
authors.forename: J L
authors.initials: JL
authors.lastname: Hopper
authors.forename: K
authors.initials: K
authors.lastname: Britt
authors.forename: M A
authors.initials: MA
authors.lastname: Henderson
authors.forename: I
authors.initials: I
authors.lastname: Haviv
authors.forename: E W
authors.initials: EW
authors.lastname: Thompson
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D000071060:Breast Density; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology*; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D006801:Humans; D042361:Mammary Glands, Human / Q000002:abnormalities* / Q000187:drug effects / Q000473:pathology; D008327:Mammography; D051379:Mice; D016513:Mice, SCID; D013629:Tamoxifen / Q000494:pharmacology*; D023822:Tissue Engineering; D016378:Tissue Transplantation; D014183:Transplantation, Heterologous
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004967:Estrogens; D013629:Tamoxifen